Literature DB >> 19508655

Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Laura Bojke1, Karl Claxton, Mark Sculpher, Stephen Palmer.   

Abstract

BACKGROUND: The characterization of uncertainty is critical in cost-effectiveness analysis, particularly when considering whether additional evidence is needed. In addition to parameter and methodological uncertainty, there are other sources of uncertainty which include simplifications and scientific judgments that have to be made when constructing and interpreting a model of any sort. These have been classified in a number of different ways but can be referred to collectively as structural uncertainties.
MATERIALS AND METHODS: Separate reviews were undertaken to identify what forms these other sources of uncertainty take and what other forms of potential methods to explicitly characterize these types of uncertainties in decision analytic models. These methods were demonstrated through application to four decision models each representing one of the four types of uncertainty.
RESULTS: These sources of uncertainty fall into four general themes: 1) inclusion of relevant comparators; 2) inclusion of relevant events; 3) alternative statistical estimation methods; and 4) clinical uncertainty.Two methods to explicitly characterize such uncertainties were identified: model selection and model averaging. In addition, an alternative approach, adding uncertain parameters to represent the source of uncertainty was also considered.The applications demonstrate that cost-effectiveness may be sensitive to these uncertainties and the methods used to characterize them. The value of research was particularly sensitive to these uncertainties and the methods used to characterize it. It is therefore important, for decision-making purposes, to incorporate such uncertainties into the modeling process.
CONCLUSION: Only parameterizing the uncertainty directly in the model can inform the decision to conduct further research to resolve this source of uncertainty.

Mesh:

Substances:

Year:  2009        PMID: 19508655     DOI: 10.1111/j.1524-4733.2008.00502.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  45 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

2.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

3.  Optimal healthcare decision making under multiple mathematical models: application in prostate cancer screening.

Authors:  Dimitris Bertsimas; John Silberholz; Thomas Trikalinos
Journal:  Health Care Manag Sci       Date:  2016-09-17

Review 4.  Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.

Authors:  Rahul Jain; Michael Grabner; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

5.  The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose.

Authors:  William Sullivan; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

Review 6.  Exploring structural uncertainty in model-based economic evaluations.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

7.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Authors:  Gerardus W J Frederix; Hossein Haji Ali Afzali; Erik J Dasbach; Robyn L Ward
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

Review 8.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 9.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

10.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.